Compare TG Therapeutics Inc (TGTX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs United Parcel Service Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while United Parcel Service Inc trades at $116 (market cap $96.18B). The key difference: United Parcel Service Inc is far larger — about 11.6× TG Therapeutics Inc's market cap, and United Parcel Service Inc pays a 5.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | UPS | |
|---|---|---|
Market Cap | $8.26B | $96.18B |
Sector | Health | Industrials |
52-Week High | $59.06 | $120.00 |
52-Week Low | $26.39 | $82.58 |
Enterprise Value | $8.50B | $119.04B |
Volume | — | 2,288,643 |
Dividend Yield | — | 5.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
UPS stock trades at $116.34, down 1.17% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results due July 28, 2026. Revenue declined to $88.66 billion in 2025, but cost controls supported a net margin of 5.94% and strong ROE of 33.41%. The company maintains solid cash flow from operations of $8.45 billion and recently paid a $1.64 dividend.
Outlook is mixed: cost-cutting and potential Q2 earnings beat offer upside, but revenue pressure and Amazon's logistics expansion pose risks. Analysts are cautiously optimistic with a $112 consensus target, slightly below current price. Key investor focus is on Q2 results and updated guidance for second-half 2026 inflection point prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
